Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 3/20 | 0.49 |
| ▸ | EGFR | P00533 | 8/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | S100A4 | P26447 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | FBP1 | P09467 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074833 | 1.00 | PTGES (0.49) | PTGESEGFRMAPTS100A4TRPV1 | |
| SCHEMBL358123 | 0.88 | EGFR (0.42) | PTGESEGFRMAPTLMNA | |
| SCHEMBL31424455 | 0.84 | PTGES (0.51) | PTGESEGFRMAPTS100A4TRPV1 | |
| SCHEMBL2250758 | 0.84 | TSHR (0.47) | MAPT | |
| SCHEMBL30074880 | 0.82 | PTGES (0.49) | PTGESEGFRMAPTLMNA | |
| SCHEMBL1490598 | 0.82 | PTGES (0.49) | PTGESEGFRMAPTLMNA | |
| SCHEMBL28058590 | 0.82 | TDP1 (0.45) | EGFRMAPT | |
| SCHEMBL26620010 | 0.82 | PTGES (0.49) | PTGESEGFRMAPTS100A4TRPV1 | |
| SCHEMBL21050767 | 0.79 | MAPT (0.37) | PTGESEGFRMAPTLMNA | |
| SCHEMBL4712057 | 0.79 | EGFR (0.39) | PTGESEGFRMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116880-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026088120-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-12492200-B2 | NLRP3 modulators | Birstol Myers-Squibb Company (US) | 2025-12-09 | — | — | US | disclosed |
| EP-3921322-B1 | PHOSPHORUS IMIDAZOQUINOLINE AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | CANWELL BIOTECH LTD (HK) | 2025-09-03 | — | — | EP | disclosed |
| US-12351580-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| WO-2025094035-A1 | TOLL-LIKE RECEPTOR AGONISTS AND CONJUGATES THEREOF | PFIZER INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-20250135006-A1 | AMPHIPHILIC TLR7/8 ADJUVANTS AND USES THEREOF | PFIZER (US) | 2025-05-01 | — | — | US | disclosed |
| US-12201627-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2025012756-A1 | AMPHIPHILIC TLR7/8 ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2025-01-16 | — | — | WO | disclosed |
| WO-2005051324-A2 | HYDROXYLAMINE AND OXIME SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005048933-A2 | OXIME SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005048945-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO RING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-02 | — | — | WO | disclosed |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-03-10 | — | — | US | disclosed |
| WO-2005018551-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018556-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2004080398-A2 | 1-AMINO 1H-IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-09-23 | — | — | WO | disclosed |
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-09 | — | — | US | disclosed |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-07-29 | — | — | US | disclosed |
| WO-2004058759-A1 | ARYL / HETARYL SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12201627-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | PTGES 396/4885EGFR 4769/4885MAPT 1593/4885 |
| US-12492200-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | PTGES 419/4885EGFR 4764/4885MAPT 1594/4885 |
| US-20260116880-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | TLR7, TLR8, TLR9 | PTGES 1999/4885EGFR 1933/4885MAPT 3673/4885 |
| US-12351580-B2 | NLRP3 modulators | NLRP3, NLRP1, NOD1 | PTGES 2479/4885EGFR 3730/4885MAPT 407/4885 |
| US-20040176367-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | PTGES 412/4885EGFR 4414/4885MAPT 3758/4885 |
| US-20050054640-A1 | 1-Amino 1H-imidazoquinolines | IL2, IFNG, IL4I1 | PTGES 412/4885EGFR 4414/4885MAPT 3758/4885 |
| US-20040147543-A1 | Aryl substituted imidazoquinolines | IL2, IFNG, IRF3 | PTGES 296/4885EGFR 3216/4885MAPT 4429/4885 |
| US-20250135006-A1 | AMPHIPHILIC TLR7/8 ADJUVANTS AND USES THEREOF | TLR7, TLR8, TLR9 | PTGES 1804/4885EGFR 1638/4885MAPT 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.